Phase IA study of TNT009 in healthy volunteers.

Trial Profile

Phase IA study of TNT009 in healthy volunteers.

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2016

At a glance

  • Drugs Sutimlimab (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 15 Jan 2016 New trial record
    • 05 Jan 2016 According to True North Therapeutics media release, the company presented the results of this trial validating TNT009's proof-of-mechanism along with the overall development plan for TNT009 at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top